Navigation Links
Hormone reduces risk of heart failure from chemotherapy
Date:8/4/2011

Recent studies have shown that the heart contains cardiac stem cells that can contribute to regeneration and healing during disease and aging. However, little is known about the molecules and pathways that regulate these cells. Now, a new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research, published by Cell Press in the August 2011 issue of the journal Cell Stem Cell, finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.

Chemotherapy with doxorubicin (DOX) has been used effectively to treat a broad range of cancers but is limited because of severe side effects, most notably heart failure. Likewise, blocking STAT3, an important factor that drives tumor growth has been associated with heart failure. To learn more about the activity of cardiac stem cells under these conditions, senior study author, Dr. Denise Hilfiker-Kleiner from the Medical School Hannover in Germany, and colleagues studied cardiac stem cells in mice that were lacking the STAT3 gene in their hearts or were treated with DOX.

Dr. Hilfiker-Kleiner and colleagues observed that in both groups of mice, cardiac stem cells displayed an impaired ability to form new blood vessels which are essential for oxygen delivery to the heart muscle. Both sets of mice produced less EPO in their heart muscle than untreated controls. The researchers went on to demonstrate that EPO binds to cardiac stem cells and is required to maintain the signaling molecules necessary for production of new blood vessels. Importantly, when the mice were given a synthetic EPO derivative at a low dose which did not affect red blood cell production, stem cell differentiation to blood vessel cells was restored and cardiac function was preserved. "Short-term EPO administration at low doses seems an attractive avenue to pursue for protecting the heart during chemotherapy and might have broader applications in cardiac regeneration," concludes Dr. Hilfiker-Kleiner.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Pioneering Hormone Therapist to Host Free Health Seminar
2. Hormone May Prevent Aggressive Breast Cancer
3. Bonding Hormone Might Help Some With Autism
4. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
5. Early On, Hormone Therapy May Raise Womens Heart Risks
6. Testicular Cancer Survivors May Have Hormone Deficiency
7. Stress hormone, depression trigger obesity in girls
8. Buy HGH Website Educates Consumers on the Pros and Cons of Human Growth Hormone Supplements
9. Hormone thought to slow aging associated with increased risk of cancer death
10. Hormone Outperforms Insulin in Diabetic Mice
11. High Hormone Level Linked to Cancer Death in Older Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... fat (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 ... its adipose filtration technology. The '398 and '324 patents cover methods and ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... 24, 2017 , ... On July 19th, the Chinese Academy ... the awarding ceremony was held successfully in Beijing. The State Health Planning Commission, ... system, and national Chinese medicine experts also attended the event, including more than ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017  New York City-based market research ... markets should be aware of.  From new products to new ... detailed in a recently completed study, Potential Pipeline Disruptors ... 1.  Age-Driven Growth - True ... been aware of the impact the growing population and, to ...
(Date:7/12/2017)...  Eli Lilly and Company (NYSE: LLY ) ... resolve pending patent litigation in the U.S. District Court for ... the Cialis ® (tadalafil) unit dose patent. This patent ... part of the agreement, Cialis exclusivity is now expected to ... "The unit dose patent for Cialis is valid and infringed ...
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology: